The orally available Btk inhibitor ibrutinib (PCI-32765) protects against osteoclast-mediated bone loss
Bone 2014;60:8-15
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Bone 2014;60:8-15
Curr. Opin. Rheumatol. 2014; 26:85–92. doi:10.1097/BOR.0000000000000012
Nat Rev Rheumatol. 2013. doi:10.1038/nrrheum.2013.168
J Pharmacol Exp Ther. 2013. DOI:10.1124/jpet.113.209304
Basic Clin Pharmacol Toxicol. 2013 Oct 24. doi: 10.1111/bcpt.12164
Pharmacological Research 2013; 76:1–8
Journal of Immunology 2013;191:3568–77
Ann Rheum Dis 2013. doi: 10.1136/annrheumdis-2013-203756
Clinical Rheumatology 2013 doi 10.1007/s10067-013-2340-1
Journal of Hematology & Oncology 2013;6:59